CPX-351 showed a 49% CR/CRi rate in older patients with secondary or high-risk AML, with 67% achieving MRD negativity. Early mortality was higher, and fewer patients underwent allo-HSCT compared to ...

** When you buy products through the links on our site, we may earn a commission that supports NRA's mission to protect, preserve and defend the Second Amendment. ** In 2017, SCCY Industries almost ...

PRINCETON, N.J.--(BUSINESS WIRE)--Celator Pharmaceuticals today announced positive clinical data in elderly patients with newly-diagnosed acute myeloid leukemia (AML) treated with CPX-351 ...

Overall survival (OS) with CPX-351 versus 7+3 in older adults with newly diagnosed, therapy-related acute myeloid leukemia (tAML): Subgroup analysis of a phase III study.